Novo Nordisk's CagriSema Data Locked as Pipeline Hopes Wrestle With a 50% Stock Wipeout

Novo Nordisk locks Phase 3 data for CagriSema vs Lilly's Tirzepatid in diabetes, with shares at half their peak and a rare profit warning weighing on outlook.

Novo Nordisk has sealed the data from a pivotal Phase 3 trial that could reshape the GLP-1 battlefield — but the Danish drugmaker enters this critical juncture with its shares trading at half their peak and a rare profit warning still fresh in investors' minds.

The study, NCT06221969, directly pits the company's experimental combination therapy CagriSema 2.4 mg against Eli Lilly's already-approved Tirzepatid 15 mg in type 2 diabetes patients on metformin. With the data lock confirmed as of April 21, 2026, Novo Nordisk is now preparing for the next regulatory steps. The full readout, expected in the second half of the year, will serve as a major catalyst for a stock that has shed roughly 50 percent from its 52-week high of 70.13 euros, last changing hands at 35.16 euros.

The stakes could hardly be higher. CagriSema — a weekly injection combining cagrilintide and semaglutide — remains experimental, while Tirzepatid is already approved across multiple markets. A win for the Danish group would strengthen its pricing power in the metabolic segment. A loss would hand Lilly an even wider moat.

A Mixed Track Record Weighs on the Narrative

The REDEFINE program has delivered an uneven scorecard. In February 2026, CagriSema failed to meet its primary endpoint in the REDEFINE-4 study, missing non-inferiority against Tirzepatid on weight loss after 84 weeks — a clear setback.

Yet the drug showed stronger results in patients without diabetes. The REDEFINE-1 trial posted a mean weight reduction of 22.7 percent after 68 weeks in overweight participants. The FDA is expected to review that application later this year, and additional data from the REDEFINE-11 study on full weight reduction potential are due in the first half of 2027.

The Profit Warning That Changed Everything

While the pipeline story grabs headlines, the financial reality has been far less forgiving. In February, Novo Nordisk issued its first profit warning in nine years, forecasting a 5 to 13 percent decline in both revenue and operating profit for 2026 on a currency-adjusted basis. That marked a sharp reversal from the 10 percent revenue growth recorded in 2025. The stock fell more than 5 percent on the news and has struggled to recover.

The technical picture underscores the pain. The relative strength index (RSI) has been plumbing deeply oversold territory, recently touching 17.8 — though it has since recovered to 25.7. From the year's low of 30.48 euros, the shares have clawed back about 15 percent, but the gap to the June 2025 high remains enormous.

A share buyback program of up to 15 billion Danish kroner over 12 months, launched in February 2026, has provided some support. By mid-April, Novo Nordisk had repurchased roughly 12.3 million B-shares for about 3.1 billion kroner.

Teen Pill Breakthrough Offers a Glimmer

Amid the gloom, there was a bright spot on April 24. Novo Nordisk announced that oral semaglutide reduced HbA1c levels by 0.83 percentage points versus placebo after 26 weeks in adolescents with type 2 diabetes — the first clinical proof of an oral GLP-1 therapy in this age group. With roughly 364,000 people under 20 living with diabetes in the US alone, the addressable market is substantial. The company plans to file for approval in the US and Europe in the second half of 2026.

Competition Intensifies From All Sides

Eli Lilly is not standing still. The US rival recently won FDA approval for "Foundayo," a daily oral weight-loss capsule that becomes the second oral GLP-1 on the market. Pricing for self-payers ranges from $149 to $349 per month, putting pressure on Novo Nordisk's pricing strategy.

Viking Therapeutics is also advancing, with its dual agonist VK2735 now in Phase 3 trials and showing impressive weight reductions. The obesity drug market is projected to balloon from roughly $26 billion in 2025 to over $133 billion by 2031 — but the number of competitors is growing just as fast.

What Lies Ahead

Novo Nordisk is working on multiple regulatory filings: for oral semaglutide in the 7.2 mg dose and for CagriSema, both destined for the US agency. The full diabetes head-to-head data will be the defining moment for the second half of 2026.

In the near term, all eyes turn to April 30, when Eli Lilly reports quarterly earnings. That release is likely to move the entire GLP-1 sector and provide a clearer picture of just how much competitive pressure Novo Nordisk is facing on the ground.